HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zubik, L. Articles by Meydani, M. Search for Related Content PubMed PubMed Citation Articles by Zubik, L. Articles by Meydani, M. Agricola Articles by Zubik, L. Articles by Meydani, M.

Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women^1,2,3,4

¹ From the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston.

Background: Test results on the bioavailability of isoflavones in the aglycone or glucoside form in Eastern and Western human subjects are contradictory.

Objective: The objective was to investigate the bioavailability of the soy isoflavones daidzein and genistein in American women with typical American dietary habits after ingestion of the aglycone or glucoside form of isoflavones.

Design: Fifteen American women aged 46 ± 6 y participated in a randomized, double-blind study. Blood samples were collected 0, 1, 2, 4, 8, 12, 24, and 48 h after consumption of aglycone or glucoside tablets with breakfast. The plasma curves for daidzein, genistein, and equol were constructed and the postprandial maximum concentration (C_max), time to the maximum concentration (t_max), and area under the curve (AUC) were determined.

Results: Isoflavone concentrations peaked early (1–2 h) in plasma and peaked again at 4–8 h. Mean C_max, t_max, and AUC values for genistein were not significantly different after ingestion of aglycone or glucoside. However, C_max and AUC values, but not t_max, were significantly higher for daidzein after aglycone ingestion, which was partly due to its higher content in the aglycone tablets. Equol appeared after 4 h and remained elevated after 48 h. Despite a higher content of daidzein in the aglycone tablets, the AUC for equol was significantly higher after ingestion of the glucoside tablets, probably because of the metabolic action of intestinal bacteria during the long intestinal transit time of glucoside.

Conclusion: The apparent bioavailability of genistein and daidzein is not different when consumed as either aglycone or glucoside by American women.

Key Words: Isoflavones • daidzein • genistein • equol • glucoside • aglycone

This article has been cited by other articles:

				C. E Rufer, A. Bub, J. Moseneder, P. Winterhalter, M. Sturtz, and S. E Kulling Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1314 - 1323. [Abstract] [Full Text] [PDF]

				M. Kano, T. Takayanagi, K. Harada, S. Sawada, and F. Ishikawa Bioavailability of Isoflavones after Ingestion of Soy Beverages in Healthy Adults J. Nutr., September 1, 2006; 136(9): 2291 - 2296. [Abstract] [Full Text] [PDF]

				A. A Franke, B. M Halm, L. J Custer, Y. Tatsumura, and S. Hebshi Isoflavones in breastfed infants after mothers consume soy. Am. J. Clinical Nutrition, August 1, 2006; 84(2): 406 - 413. [Abstract] [Full Text] [PDF]

				K. D. R. Setchell and S. J. Cole Method of Defining Equol-Producer Status and Its Frequency among Vegetarians J. Nutr., August 1, 2006; 136(8): 2188 - 2193. [Abstract] [Full Text] [PDF]

				K. Decroos, E. Eeckhaut, S. Possemiers, and W. Verstraete Administration of Equol-Producing Bacteria Alters the Equol Production Status in the Simulator of the Gastrointestinal Microbial Ecosystem (SHIME) J. Nutr., April 1, 2006; 136(4): 946 - 952. [Abstract] [Full Text] [PDF]

				A. Cassidy, J. E. Brown, A. Hawdon, M. S. Faughnan, L. J. King, J. Millward, L. Zimmer-Nechemias, B. Wolfe, and K. D.R. Setchell Factors Affecting the Bioavailability of Soy Isoflavones in Humans after Ingestion of Physiologically Relevant Levels from Different Soy Foods J. Nutr., January 1, 2006; 136(1): 45 - 51. [Abstract] [Full Text] [PDF]

				C. Manach, G. Williamson, C. Morand, A. Scalbert, and C. Remesy Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies Am. J. Clinical Nutrition, January 1, 2005; 81(1): 230S - 242S. [Abstract] [Full Text] [PDF]

				G. Maskarinec, A. A. Franke, A. E. Williams, S. Hebshi, C. Oshiro, S. Murphy, and F. Z. Stanczyk Effects of a 2-Year Randomized Soy Intervention on Sex Hormone Levels in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1736 - 1744. [Abstract] [Full Text] [PDF]

				Y. Zheng, S.-O. Lee, M. A. Verbruggen, P. A. Murphy, and S. Hendrich The Apparent Absorptions of Isoflavone Glucosides and Aglucons Are Similar in Women and Are Increased by Rapid Gut Transit Time and Low Fecal Isoflavone Degradation J. Nutr., October 1, 2004; 134(10): 2534 - 2539. [Abstract] [Full Text] [PDF]

				W.-F. Chen and M.-S. Wong Genistein Enhances Insulin-Like Growth Factor Signaling Pathway in Human Breast Cancer (MCF-7) Cells J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2351 - 2359. [Abstract] [Full Text] [PDF]

				J. W. Erdman Jr., T. M. Badger, J. W. Lampe, K. D.R. Setchell, and M. Messina Not All Soy Products Are Created Equal: Caution Needed in Interpretation of Research Results J. Nutr., May 1, 2004; 134(5): 1229S - 1233S. [Abstract] [Full Text] [PDF]

				J. D. Wagner, D. C. Schwenke, K. A. Greaves, L. Zhang, M. S. Anthony, R. M. Blair, M. K. Shadoan, and J. K. Williams Soy Protein With Isoflavones, but not an Isoflavone-Rich Supplement, Improves Arterial Low-Density Lipoprotein Metabolism and Atherogenesis Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2241 - 2246. [Abstract] [Full Text] [PDF]